Filing Flows › Comparisons › SRPT vs PTCT
Sarepta Therapeutics vs PTC Therapeutics: SRPT and PTCT compared
Sarepta Therapeutics is the larger company: $381M of revenue in its latest quarter (Q3 2026) against $358M for PTC Therapeutics (Q3 2026). PTC Therapeutics is growing faster (+70% against -4% a year earlier). PTC Therapeutics is more profitable, with an operating margin of 7.0% against -2.4%.
Where the money goes: SRPT and PTCT
Sarepta Therapeutics (SRPT) · Q3 2026
Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart follows the revenue to costs, profit and cash.
PTC Therapeutics (PTCT) · Q3 2026
PTC Therapeutics, Q3 2026: revenue $358M (+70% year over year), operating margin 7.0%, net loss $51.7M, operating cash flow −$25.3M. The chart follows the revenue to costs, profit and cash.
| Sarepta Therapeutics (SRPT) | PTC Therapeutics (PTCT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $381M | $358M |
| Revenue growth, Y/Y | -4% | +70% |
| Operating margin | -2.4% | 7.0% |
| Net earnings | −$28.5M | −$51.7M |
| Net margin | -7.5% | -14.4% |
| Operating cash flow | $60.0M | −$25.3M |
| Free cash flow | $57.0M | — |
| Market value | $1.9B | $5.5B |
| Analysts’ mean target | $21.68 | $100.47 |
Where the revenue comes from
Sarepta Therapeutics
- Pmo Products: $240M (63%)
- Elevidys: $83.5M (22%)
- Other revenues: $57.6M (15%)
PTC Therapeutics
- Net product revenue: $276M (77%)
- Royalty revenue: $81.7M (23%)
- Collaboration and license revenue: $229K (0%)
Questions
Which is bigger, Sarepta Therapeutics or PTC Therapeutics?
Sarepta Therapeutics is the larger company: $381M of revenue in its latest quarter (Q3 2026) against $358M for PTC Therapeutics (Q3 2026).
Is Sarepta Therapeutics or PTC Therapeutics growing faster?
PTC Therapeutics is growing faster (+70% against -4% a year earlier).
Which is more profitable, Sarepta Therapeutics or PTC Therapeutics?
PTC Therapeutics is more profitable, with an operating margin of 7.0% against -2.4%.
More: Sarepta Therapeutics earnings · how Sarepta Therapeutics makes money · PTC Therapeutics earnings · how PTC Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.